Authors: Jianmei Huang, BMed , Chungyung Keung, MMed , Li Ma, MMed , Jingjing Zhao, BMed , Zhiqiang Xue, PhD , Shuxian Zhang, BMed , Yuan Chen, BMed , Lin Tao, MMed , Qingyang Liu, PhD , Cecilia Persson, PhD, Inna Prygova, MD , Weimin Song, MMed
Abstract: AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting. Secondary variables included effectiveness, patient and physician satisfaction in each cycle, and injection practice details. In this non-interventional, multicenter study conducted in China, participants received 3 injection cycles of aboBoNT-A in the GL area, 3 to 6 months apart, with follow-up at Week 3, before the next treatment, and at end-of-study. Assessments included satisfaction questionnaires, GL wrinkle severity, and safety. At 3 weeks after the third injection, 100% of patients (N = 204) were satisfied with treatment (very satisfied: 71.1%; satisfied: 28.9%, primary endpoint), and physicians were very satisfied/satisfied with overall treatment outcome in 99.5% of patients. Physicians reported ≥1-grade improvement in GL severity at maximum frown in ≥90% of patients at 3 weeks in each cycle and in ≥64% at ∼5 months post-treatment (at next treatment). For ≥99% of patients, physicians would recommend aboBoNT-A to colleagues. The treatment was well tolerated, with no new safety findings. All patients were satisfied with aboBoNT-A GL treatment after 3 injection cycles in this Chinese real-world study. As supported by multiple outcome measures, both patients and physicians reported high satisfaction with treatment and long-lasting improvement in wrinkle severity across single or repeat cycles. Treatment was well tolerated.
